BR112022009773A2 - KIT TO PREPARE A NANOPARTICLES COMPOSITION - Google Patents

KIT TO PREPARE A NANOPARTICLES COMPOSITION

Info

Publication number
BR112022009773A2
BR112022009773A2 BR112022009773A BR112022009773A BR112022009773A2 BR 112022009773 A2 BR112022009773 A2 BR 112022009773A2 BR 112022009773 A BR112022009773 A BR 112022009773A BR 112022009773 A BR112022009773 A BR 112022009773A BR 112022009773 A2 BR112022009773 A2 BR 112022009773A2
Authority
BR
Brazil
Prior art keywords
kit
prepare
drug
composition
nanoparticles
Prior art date
Application number
BR112022009773A
Other languages
Portuguese (pt)
Inventor
Jin Lee So
Hoon Kim Sang
Young Park Joon
Yeong Nam Hye
Yeon Son Ji
Original Assignee
Samyang Holdings Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Samyang Holdings Corp filed Critical Samyang Holdings Corp
Publication of BR112022009773A2 publication Critical patent/BR112022009773A2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Abstract

KIT PARA PREPARAR UMA COMPOSIÇÃO DE NANOPARTÍCULAS. A presente invenção refere-se a um kit para preparar uma composição de nanopartículas para entrega de fármacos e, mais especificamente, a um kit para preparar uma composição de nanopartículas para entrega de fármacos, em que o kit é projetado de modo que o kit não compreenda um sal de ácido polilático e as nanopartículas contendo um fármaco encapsulado nas mesmas podem ser facilmente formadas simplesmente misturando um copolímero em bloco anfifílico, um composto catiônico e um fármaco como componentes do kit.KIT TO PREPARE A NANOPARTICLES COMPOSITION. The present invention relates to a kit for preparing a nanoparticle composition for drug delivery, and more specifically, a kit for preparing a nanoparticle composition for drug delivery, wherein the kit is designed so that the kit does not comprises a polylactic acid salt and nanoparticles containing a drug encapsulated therein can be easily formed by simply mixing an amphiphilic block copolymer, a cationic compound and a drug as kit components.

BR112022009773A 2019-11-22 2020-11-19 KIT TO PREPARE A NANOPARTICLES COMPOSITION BR112022009773A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20190151227 2019-11-22
PCT/KR2020/016359 WO2021101265A1 (en) 2019-11-22 2020-11-19 Kit for preparing nanoparticle composition for drug delivery

Publications (1)

Publication Number Publication Date
BR112022009773A2 true BR112022009773A2 (en) 2022-08-09

Family

ID=75980970

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022009773A BR112022009773A2 (en) 2019-11-22 2020-11-19 KIT TO PREPARE A NANOPARTICLES COMPOSITION

Country Status (9)

Country Link
US (1) US20230017360A1 (en)
EP (1) EP4062908A4 (en)
JP (1) JP2023503910A (en)
KR (1) KR102607199B1 (en)
CN (1) CN114980870A (en)
AU (1) AU2020387478A1 (en)
BR (1) BR112022009773A2 (en)
CA (1) CA3159021A1 (en)
WO (1) WO2021101265A1 (en)

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2958076B2 (en) * 1990-08-27 1999-10-06 株式会社ビタミン研究所 Multilamellar liposome for gene transfer and gene-captured multilamellar liposome preparation and method for producing the same
TW203552B (en) * 1992-02-18 1993-04-11 J Baroody Lloyd Compositions of clindamycin and benzoyl peroxide for acne treatment
JP4335310B2 (en) * 1995-06-07 2009-09-30 ザ ユニバーシティ オブ ブリティッシュ コロンビア Lipid-nucleic acid particles prepared through hydrophobic lipid-nucleic acid complex intermediates and use for gene transfer
BR9702049B1 (en) * 1996-01-31 2010-08-10 dispensing system containing two compartments for simultaneous dosing of two aqueous compositions.
US6235310B1 (en) * 1997-04-04 2001-05-22 Valentis, Inc. Methods of delivery using cationic lipids and helper lipids
DE10040610A1 (en) * 2000-08-16 2002-03-07 Schwabe Willmar Gmbh & Co Flavonhaltige plant extract solutions with improved storage and heat stability
US10292932B2 (en) * 2008-12-26 2019-05-21 Samyang Biopharmaceuticals Corporation Polymeric micelle particle comprising anionic drugs and method of preparing the same
EP2833869B1 (en) * 2012-04-04 2020-10-28 Samyang Biopharmaceuticals Corporation Method of preparing composition for delivering an anionic drug
KR101507119B1 (en) * 2013-05-31 2015-03-30 주식회사 바이오리더스 Mucoadhesive Poly-γ-glutamic acid Nanomicelles and Drug Delivery Vector Use thereof
AU2016324450B2 (en) * 2015-09-15 2019-04-18 Samyang Holdings Corporation Pharmaceutical composition containing anionic drug, and preparation method therefor
NZ743320A (en) * 2015-12-18 2019-03-29 Samyang Biopharmaceuticals Method for preparing polymeric micelle containing anionic drug
KR20190127277A (en) * 2018-05-04 2019-11-13 주식회사 삼양바이오팜 Polymeric nanoparticle composition for delivering mRNA and preparation method thereof

Also Published As

Publication number Publication date
KR102607199B1 (en) 2023-11-29
AU2020387478A8 (en) 2022-06-30
EP4062908A4 (en) 2024-01-24
KR20210064072A (en) 2021-06-02
EP4062908A1 (en) 2022-09-28
CA3159021A1 (en) 2021-05-27
CN114980870A (en) 2022-08-30
US20230017360A1 (en) 2023-01-19
JP2023503910A (en) 2023-02-01
WO2021101265A1 (en) 2021-05-27
AU2020387478A1 (en) 2022-06-16

Similar Documents

Publication Publication Date Title
BR112015005940A2 (en) process for the preparation of therapeutic nanoparticles
BR112014011841A2 (en) hydrophobic drug delivery material, method for producing the same and methods for delivering a drug delivery composition
BR112015023629A2 (en) abiraterone acetate formulation
CU20170172A7 (en) 4,6-DIAMINOQUINOLIN-3-CARBONITRILS SUBSTITUTED USEFUL AS ANALGESIC, ANTIPIRÉTIC OR ANTIINFLAMATORIOS AND ANTINEOPLÁSICOS AGENTS
BR112015022047A8 (en) use of a composition comprising nanoparticles containing a limo family drug and an albumin
BR112015023658A2 (en) stabilized release modified vitamin D formulation and method of administration of this
BR112015023922A2 (en) pharmaceutical composition comprising an ampk activator and a serotonergic agent and methods of using these
MX2015011752A (en) Methods of treating lung cancer.
BR112015001414A2 (en) antiderive composition
BR112015022972A2 (en) s-ketamine hydrochloride pharmaceutical composition
BR112012028726A2 (en) cyclodextrime complexation methods for the formulation of peptide proteasome inhibitors
BR112015011430A2 (en) composition for immediate and prolonged release
BR112013022213A2 (en) parenteral administration of tapentadol
BR112015015137A2 (en) polyethylene based structure
PH12016500766A1 (en) Age-tailored nutritional compositions with a varying protein content
BR112015014996A2 (en) controlled distribution whitening compositions
BR112016017897A8 (en) use of heterocyclic diamino carboxamide compound in the treatment of axl-related cancer, pharmaceutical composition and combination
MX367926B (en) Pharmaceutical composition for a sustained release of lanreotide.
BR112017024735A2 (en) Microcapsule suspension
BR112017022846A2 (en) tamper-proof fixed dose combination that provides rapid release of two different particle drugs
NZ713342A (en) Fine dry particulate retinoid active agent compositions and topical formulations including the same
BR112022012118A2 (en) KIT TO PREPARE A NANOPARTICLES COMPOSITION
BR112015001640A2 (en) Formulations and production methods of formulations for use in colonic evacuation
BR112015014092A2 (en) transmucosal oral administration of glatiramer acetate
BR112015000275A2 (en) use of a myrtle extract as an anti-biofilm agent e.g. acnes